Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 29;36(36):JCO2018792259.
doi: 10.1200/JCO.2018.79.2259. Online ahead of print.

Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers

Affiliations
Review

Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers

Sabina Signoretti et al. J Clin Oncol. .

Abstract

Renal cell carcinoma (RCC) is not a single entity but includes various tumor subtypes that have been identified on the basis of either characteristic pathologic features or distinctive molecular changes. Clear cell RCC is the most common type of RCC and is characterized by dysregulation of the von Hippel Lindau/hypoxia-inducible factor pathway. Non-clear cell RCC represents a more heterogeneous group of tumors with diverse histopathologic and molecular features. In the past two decades, the improved understanding of the molecular landscape of RCC has led to the development of more effective therapies for metastatic RCC, which include both targeted agents and immune checkpoint inhibitors. Because only subsets of patients with metastatic RCC respond to a given treatment, predictive biomarkers are needed to guide treatment selection and sequence. In this review, we describe the key histologic features and molecular alterations of RCC subtypes and discuss emerging tissue-based biomarkers of response to currently available therapies for metastatic disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kovacs G, Akhtar M, Beckwith BJ, et al. : The Heidelberg classification of renal cell tumours. J Pathol 183:131-133, 1997 - PubMed
    1. Eble JN, Sauter G, Epstein JI, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs (ed3). Lyon, France, IARC Press, 2004
    1. Moch H, Humphrey PA, Ulbright TM, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs (ed 4). Lyon, France, IARC, 2016 - PubMed
    1. Reuter VE, Tickoo SK: Differential diagnosis of renal tumours with clear cell histology. Pathology 42:374-383, 2010 - PubMed
    1. Cancer Genome Atlas Research Network : Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49, 2013 - PMC - PubMed